Oncolytics Biotech Inc has been granted U.S. Patent 6,528,305 entitled "Method of Producing Infectious Reovirus". This patent covers a method of producing infectious mammalian reovirus, which is developed to be suitable for clinical administration to mammals, including humans, on a cost effective basis.
"With the issuance of this U.S. patent, we continue to strengthen the Company's intellectual property position. The Company is continuing to broaden its position in this novel therapeutic area. We currently have over 100 additional patent applications pending worldwide and we expect to continue to expand our patent portfolio for Reolysin," said Dr. Matt Coffey, Vice President of Product Development.